Niklas Hedberg, Chief Pharmacist for the Dental and Pharmaceuticals Benefits Agency in Sweden, chairs the executive board for the European Network for Health Technology Assessment known as EUnetHTA. “We typically see that there are a lot of comparative questions that are not or even cannot be answered by traditional randomized control trials,” he explains. “Anything that is outside the typical randomized controlled trial scope is probably going to be of increasing importance for the relative effectiveness and relative cost evaluation.” Mr. Hedberg hosted the EUnetHTA Town Hall at DIA Europe 2019.